At Novo Nordisk, we believe in change. We are parents, colleagues, neighbors, and friends — people living with the complexities of serious diseases. And we believe in the combination of science and soul to help nurture each other back to good health.

For almost 100 years, we have been driving change to defeat diabetes, which has given us the experience and capability to help defeat other serious chronic diseases, including obesity, hemophilia and growth hormone disorders. 

We work for a future where lives are not limited—and we do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure the diseases we treat.

From our labs to our factory floors, we are discovering and developing innovative biological medicines and making them accessible to patients who need them.

Headquarters in Plainsboro, NJ, with locations in 7 states

Employing nearly 6000 people

4 million people in the U.S. using our medicines

Plainsboro, NJ Novo Nordisk office

Our U.S. headquarters in Plainsboro, New Jersey plays a critical role in the vibrancy of the life sciences industry in New Jersey. We are responsible for sales and marketing of all Novo Nordisk products in the U.S. and manage clinical trials in the U.S. Our LEED-certified headquarters building is modeled on principles of functionality, innovation, openness, quality and aesthetics - offering a space that promotes collaboration and creativity.

For additional information

We have two stem cell research and clinical manufacturing facilities located in the San Francisco Bay area: University of California, San Francisco (UCSF) in San Francisco’s Mission District, and the other in Fremont.

These teams leverage stem cell technology to find new treatments for patients with diabetes and heart failure and are exploring other high need areas such as neurology and ophthalmology.

Indianapolis, IN Novo Nordisk office

Novo Nordisk Research Center Indianapolis, Inc. (NNRCII) was established in late 2015 when we acquired Calibrium and MB2, two private companies co-founded by Dr. Richard DiMarchi that were focused on developing peptide-based drug candidates for treatment of diabetes and obesity. Today, NNRCII is the home of an elite research team working in unison within our global research mission to transform the management of cardio-metabolic diseases.

For additional information

The Novo Nordisk Boston Innovation Hub is the headquarters for Global R&D Business Development across all of our therapeutic and technology areas.  Containing functions in Business Development, Search & Evaluation and Alliance Management, the Boston Innovation Hub houses the full complement of business functions needed for our external partnering activities. Having a physical presence in the one of the world’s largest life sciences ecosystem is part of our strategy to access the high level of innovation that the US has to offer.  

For additional information

West Lebanon, NH Novo Nordisk office

Located in West Lebanon, New Hampshire, Novo Nordisk U.S. Bio Production, Inc. (NNUSBPI), is a biopharmaceutical manufacturing facility that works to produce trusted products for people living with the rare bleeding disorder known as hemophilia. Our key contribution is to discover and develop safe, innovative biological medicines and make them accessible to the people who need them. We work toward a future where all people living with hemophilia, with or without inhibitors, have the opportunity to live the life they desire.

For additional information

Computer graphic of administration building for future facilities that will produce active pharmaceutical ingredients (API) for both oral semaglutide and some current and future GLP-1 and insulin products

Our first U.S. manufacturing facility for diabetes and obesity medicines was established in Clayton, NC in 1993. The facility has expanded rapidly to meet the increasing demand for our products, both locally and globally. We are now investing $2 billion in a new active pharmaceutical ingredient production facility in Clayton and we are opening a facility in Durham, NC to support a new diabetes treatment.

For additional information

Seattle, WA Novo Nordisk office

Our research center in Seattle is focused on early discovery projects within diabetes, obesity and chronic kidney disease. The unit's scientists apply advanced technologies to identify protein-based therapies for obesity and the prevention and treatment of type 1 diabetes. Furthermore, a dedicated team of device engineers are working with digitalization and connectivity of medical devices for improved treatment outcome.

For additional information

The Novo Nordisk Way is a set of guiding principles that underpins every decision we make. It describes who we are, how we work and what we want to achieve, and sets a clear direction for our company and our employees. Ultimately, it’s a promise we make to each other — and to the millions of patients all over the world who rely on our products to lead full and healthy lives.

Novo Nordisk Way is our way.

In 1923, our Danish founders began a journey to change diabetes. Today, we are thousands of employees across the world with the passion, skills and commitment to drive change to defeat diabetes and other serious chronic diseases.

  • We aim to lead in all disease areas in which we are active.
  • Our key contribution is to discover and develop innovative biological medicines and make them accessible to patients throughout the world.
  • Growing our business and delivering competitive financial results is what allows us to help patients live better lives, offer an attractive return to our shareholders and contribute to our communities.
  • Our business philosophy is one of balancing financial, social and environmental considerations.
  • We are open and honest, ambitious and accountable, and treat everyone with respect.
  • We offer opportunities for our people to realize their potential.
  • We never compromise on quality and business ethics.

Every day, we must make difficult choices, always keeping in mind what is best for patients, our employees and our shareholders in the long run.

It's our way. It's the Novo Nordisk Way.

production sites in nine countries (Algeria, Brazil, China, Denmark, France, Japan, Russia, UK and US).

research and development centres in five countries (China, Denmark, India, UK and US).

of our employees are located in Denmark.

number of countries where we sell our products.

We are a proud life science company united by a common job to discover better treatments for people living with a serious chronic disease. 

Our industry is dynamic. And the scientific understanding of the diseases we treat and the people living with them, improves every day. This is a constant reminder that what got us to where we are today is not necessarily what will make us successful in the future. 

As an employer, we recognize the need to embrace experimentation and strive for diversity and inclusion to help make better decisions by ensuring that multiple perspectives are considered.

Together, we’re life changing.

Marie Darting and Pernille Thomasen, Novo Nordisk Denmark

We work in close collaboration with leading universities and biotech companies worldwide to collaborate and speed up new drug discovery.

We continuously seek new partners with whom we share complementary capabilities and mutual interests, and openly share novel peptide and protein analogues, and antibodies for preclinical research.

We offer easy and free access to selected high-quality and well-characterised compounds to curious and passionate scientists from around the world.